STOCK TITAN

iCAD to Report Second Quarter 2021 Financial Results on Thursday, August 5

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

NASHUA, N.H., July 22, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter and six-months ended June 30, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Thursday, August 5.

Thursday, August 5th @ 4:30pm ET
Domestic:888-254-3590
International:323-994-2082
Conference ID:6177004
Webcast:    
http://public.viavid.com/index.php?id=145901

About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.

Contact:
Media Inquiries:
Jessica Burns, iCAD  
+1-201-423-4492
jburns@icadmed.com

Investor Relations:
Jeremy Feffer, LifeSci Advisors
+ 1-212-915-2568
jeremy@lifesciadvisors.com


Icad Inc

NASDAQ:ICAD

ICAD Rankings

ICAD Latest News

ICAD Stock Data

Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
Electronic Technology, Computer Peripherals, Technology Services, Packaged Software, Manufacturing, Small Arms, Ordnance, and Ordnance Accessories Manufacturing

About ICAD

icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.